Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Juluca Dolutegravir rilpivirine HIV infection Reimburse with clinical criteria and/or conditions Complete
Dupixent dupilumab atopic dermatitis Do not reimburse Complete
Besponsa Inotuzumab Ozogamicin Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete
Lonsurf Trifluridine and Tipiracil Metastatic Colorectal Cancer Do not reimburse Complete
Alecensaro Alectinib Locally advanced or metastatic ALK+ NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete
Symtuza Darunavir/cobicistat/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Fasenra benralizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete
Duodopa Levodopa / carbidopa (Drug Plan Submission) Parkinson's disease Reimburse with clinical criteria and/or conditions Complete
Probuphine buprenorphine hydrochloride Opioid drug dependence, treatment Reimburse with clinical criteria and/or conditions Complete